Circadian Disruption and Breast Cancer: From Melatonin to Clock Genes

The global impact of breast cancer is large and growing. It seems clear that something about modern life is the culprit, yet there is thus far a lack of satisfactory explanations for most of the increases in risk as societies industrialize. Support has developed for a possible role of “circadian disruption,” particularly from an altered-lighted environment (such as light at night). Lighting during the night of sufficient intensity can disrupt circadian rhythms, including reduction of circulating melatonin levels and resetting of the circadian pacemaker of the suprachiasmatic nuclei. Reduced melatonin may increase breast cancer risk through several mechanisms, including increased estrogen production and altered estrogen receptor function. The genes that drive the circadian rhythm are emerging as central players in gene regulation throughout the organism, particularly for cell-cycle regulatory genes and the genes of apoptosis. Aspects of modern life that can disrupt circadian rhythms during the key developmental periods (eg, in utero and during adolescence) may be particularly harmful. Epidemiologic studies should consider gene and environment interactions such as circadian gene variants and shift work requirements on the job.

[1]  Charles A Czeisler,et al.  High sensitivity of the human circadian melatonin rhythm to resetting by short wavelength light. , 2003, The Journal of clinical endocrinology and metabolism.

[2]  T. Yoshimura,et al.  Spectral sensitivity of photoreceptors mediating phase-shifts of circadian rhythms in retinally degenerate CBA/J (rd/rd) and normal CBA/N (+/+) mice , 1996, Journal of Comparative Physiology A.

[3]  C. Nagata,et al.  Trends in the incidence rate and risk factors for breast cancer in Japan , 1997, Breast Cancer Research and Treatment.

[4]  Tore Tynes,et al.  Incidence of breast cancer in Norwegian female radio and telegraph operators , 1996, Cancer Causes & Control.

[5]  S H Moolgavkar,et al.  Temporal trends in breast cancer. , 1982, American journal of epidemiology.

[6]  David E. Blask,et al.  Growth and Fatty Acid Metabolism of Human Breast Cancer (MCF-7) Xenografts in Nude Rats: Impact of Constant Light-Induced Nocturnal Melatonin Suppression , 2003, Breast Cancer Research and Treatment.

[7]  David E. Blask,et al.  Pineal melatonin inhibition of tumor promotion in theN-nitroso-N-methylurea model of mammary carcinogenesis: potential involvement of antiestrogenic mechanisms in vivo , 2005, Journal of Cancer Research and Clinical Oncology.

[8]  I. Fentiman,et al.  Melatonin and breast cancer: a prospective study. , 2004, Journal of the National Cancer Institute.

[9]  B. H. Miller,et al.  Coordinated Transcription of Key Pathways in the Mouse by the Circadian Clock , 2002, Cell.

[10]  H. Ra Does blindness protect against cancers , 1998 .

[11]  D. Blask,et al.  Physiological melatonin inhibition of human breast cancer cell growth in vitro: evidence for a glutathione-mediated pathway. , 1997, Cancer research.

[12]  J. Horne,et al.  A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. , 1976, International journal of chronobiology.

[13]  L. Fu,et al.  The circadian clock: pacemaker and tumour suppressor , 2003, Nature Reviews Cancer.

[14]  B. Macmahon Cohort fertility and increasing breast cancer incidence , 1958, Cancer.

[15]  Johnni Hansen,et al.  Increased Breast Cancer Risk among Women Who Work Predominantly at Night , 2001, Epidemiology.

[16]  J. Rizzo,et al.  Suppression of melatonin secretion in some blind patients by exposure to bright light. , 1995, The New England journal of medicine.

[17]  A C Bird,et al.  Relationship between melatonin rhythms and visual loss in the blind. , 1997, The Journal of clinical endocrinology and metabolism.

[18]  R. Foster,et al.  Regulation of the mammalian pineal by non-rod, non-cone, ocular photoreceptors. , 1999, Science.

[19]  Josephine Arendt,et al.  A length polymorphism in the circadian clock gene Per3 is linked to delayed sleep phase syndrome and extreme diurnal preference. , 2003, Sleep.

[20]  N. Kajimura,et al.  Alleic variants of human melatonin 1a receptor: function and prevalence in subjects with circadian rhythm sleep disorders. , 1999, Biochemical and biophysical research communications.

[21]  W Gruen,et al.  Seasonal Variation in Human Illumination Exposure at Two Different Latitudes , 1995, Journal of biological rhythms.

[22]  D. Trichopoulos Hypothesis: does breast cancer originate in utero? , 1990, The Lancet.

[23]  R. Stevens,et al.  Electric power use and breast cancer: a hypothesis. , 1987, American journal of epidemiology.

[24]  G. Brainard,et al.  Action Spectrum for Melatonin Regulation in Humans: Evidence for a Novel Circadian Photoreceptor , 2001, The Journal of Neuroscience.

[25]  Francis Lévi,et al.  Host circadian clock as a control point in tumor progression. , 2002, Journal of the National Cancer Institute.

[26]  M. Lippman,et al.  ROLE OF PINEAL GLAND IN ÆTIOLOGY AND TREATMENT OF BREAST CANCER , 1978, The Lancet.

[27]  R. V. Van Gelder Making (a) sense of non-visual ocular photoreception. , 2003, Trends in neurosciences.

[28]  S. Pocock,et al.  Incidence , , 2018 .

[29]  M Feychting,et al.  Reduced Cancer Incidence among the Blind , 1998, Epidemiology.

[30]  F. Bray,et al.  Cancer burden in the year 2000. The global picture. , 2001, European journal of cancer.

[31]  L. E. Anderson,et al.  Effect of constant light on DMBA mammary tumorigenesis in rats , 2000, Cancer Letters.

[32]  R. Stevens,et al.  Inverse association between breast cancer incidence and degree of visual impairment in Finland , 1999, British Journal of Cancer.

[33]  D. P. King,et al.  A CLOCK polymorphism associated with human diurnal preference. , 1998, Sleep.

[34]  R. Hahn,et al.  Profound bilateral blindness and the incidence of breast cancer. , 1991, Epidemiology.

[35]  B. Griefahn The validity of the temporal parameters of the daily rhythm of melatonin levels as an indicator of morningness , 2002, Chronobiology international.

[36]  T. Wehr,et al.  Photoperiodism in Humans and Other Primates: Evidence and Implications , 2001, Journal of biological rhythms.

[37]  Peng Huang,et al.  The Circadian Gene Period2 Plays an Important Role in Tumor Suppression and DNA Damage Response In Vivo , 2002, Cell.

[38]  P. Siiteri,et al.  Placental characteristics and reduced risk of maternal breast cancer. , 2001, Journal of the National Cancer Institute.

[39]  L. E. Anderson,et al.  Electric power, pineal function, and the risk of breast cancer , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[40]  R. Troisi,et al.  In-utero and early life exposures in relation to risk of breast cancer , 1999, Cancer Causes & Control.

[41]  Michael Menaker,et al.  Circadian Photoreception , 2003, Science.

[42]  Tongzhang Zheng,et al.  Period3 structural variation: a circadian biomarker associated with breast cancer in young women. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[43]  S. Hill,et al.  The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system. , 1992, Cancer letters.

[44]  Mark S. Rea,et al.  Light in the Built Environment: Potential role of Circadian Disruption in Endocrine Disruption and Breast Cancer , 2001, Cancer Causes & Control.

[45]  M. Karásek,et al.  Melatonin in humans. , 2006, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[46]  G. Maestroni,et al.  Therapeutic potential of melatonin in immunodeficiency states, viral diseases, and cancer. , 1999, Advances in experimental medicine and biology.

[47]  D A Newsome,et al.  Light suppresses melatonin secretion in humans. , 1980, Science.

[48]  A. Auvinen,et al.  Incidence of cancer among Finnish airline cabin attendants, 1967-92 , 1995, BMJ.

[49]  J. Russo,et al.  Mammary gland neoplasia in long-term rodent studies. , 1996, Environmental health perspectives.

[50]  Prahlad T. Ram,et al.  Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells , 2004, Breast Cancer Research and Treatment.

[51]  R. N. Gelder Making (a) sense of non-visual ocular photoreception , 2003, Trends in Neurosciences.

[52]  R. Kronauer,et al.  Stability, precision, and near-24-hour period of the human circadian pacemaker. , 1999, Science.

[53]  B. Griefahn,et al.  Melatonin synthesis: a possible indicator of intolerance to shiftwork. , 2002, American journal of industrial medicine.

[54]  R. Reiter,et al.  Melatonin: an antioxidant in edible plants. , 2002, Annals of the New York Academy of Sciences.

[55]  J. West,et al.  Developmental Alcohol and Circadian Clock Function , 2001, Alcohol research & health : the journal of the National Institute on Alcohol Abuse and Alcoholism.

[56]  R. Stevens Epidemiology of Uriniary Melatonin in Women and Its Relation to Other Hormones and Night Work , 2005, Cancer Epidemiology Biomarkers & Prevention.

[57]  T. Mack,et al.  Puberty and genetic susceptibility to breast cancer in a case-control study in twins. , 2003, The New England journal of medicine.

[58]  F Laden,et al.  Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. , 2001, Journal of the National Cancer Institute.

[59]  M. Mhatre,et al.  Effect of melatonin on mammary carcinogenesis in intact and pinealectomized rats in varying photoperiods. , 1984, Cancer research.

[60]  T. Paunio,et al.  Circadian Clock-Related Polymorphisms in Seasonal Affective Disorder and their Relevance to Diurnal Preference , 2003, Neuropsychopharmacology.

[61]  G. Eichele,et al.  The mPer2 gene encodes a functional component of the mammalian circadian clock , 1999, Nature.

[62]  R. Stevens,et al.  Night shift work, light at night, and risk of breast cancer. , 2001, Journal of the National Cancer Institute.

[63]  Cantab Ma John Crighton Bramwell. , 1976 .

[64]  T. Tynes,et al.  Risk of breast cancer among Norwegian women with visual impairment , 2001, British Journal of Cancer.